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Abstract  
Purpose Beyond intravenous thrombolysis (IVT), evidence is lacking on acute treatment of 
minor stroke caused by large artery occlusion. To identify candidates for additional 
endovascular therapy, we aimed to determine the frequency of non-hemorrhagic early 
neurological deterioration (nhEND) in patients with IVT-treated minor stroke caused by 
occlusion of large proximal and distal cerebral arteries. Secondary aims were to establish risk 
factors for nhEND, and report three month outcomes in patients with and without nhEND. 
Method We analysed data from the SITS-International Stroke Thrombolysis Register on 2553 
patients with IVT-treated minor stroke (NIHSS scores 0-5) and available arterial occlusion 
data. nhEND was defined as an increase in NIHSS score ≥4 at 24 hours, without parenchymal 
hematoma on follow-up imaging within 22-36 hours. 
Findings The highest frequency of nhEND was seen in 30% of patients with terminal internal 
carotid (ICA-T) or tandem occlusions (ICA+MCA) (adjusted OR: 10.3 (95% CI 4.3-24.9), 
p<0.001), and 17% in extracranial carotid occlusions (aOR 4.3 (2.5-7.7), p<0.001), versus 
3.1% in those with no occlusion. Proximal MCA-M1 occlusions had nhEND in 9% (aOR 2.1 
(0.97-4.4), p=0.06). Among patients with any occlusion and nhEND, 77% were dead or 
dependent at 3 months. 
Conclusions Patients with minor stroke caused by ICA occlusion, with or without tandem 
MCA involvement, are at high risk of disabling deterioration, despite IVT treatment. Acute 
vessel imaging contributes usefully even in minor stroke to identify and consider 
endovascular treatment, or intensive monitoring at a comprehensive stroke center, for patients 
at high risk of neurological deterioration.  
Introduction 
Patients with acute minor stroke caused by large artery occlusion pose a particular challenge 
in acute clinical decision making. Intravenous thrombolysis is the mainstay therapy for acute 
ischemic stroke regardless of severity, with firm evidence of benefit in cases with relatively 
mild symptoms.1 Large cerebral artery occlusions typically lead to more severe stroke.2, 3 
However, in the presence of a complete circle of Willis and a well-developed collateral 
circulation, patients with proximal arterial occlusions may at times present with only 
relatively mild symptoms. It is a well-known clinical phenomenon that such patients can 
suffer significant clinical deterioration as the initial hours pass.4-8 A common mechanism 
behind this course of events is infarct growth beyond the initial infarct zone, due to collateral 
circulation failure, thrombus extension, or secondary thromboembolism.9-13 Early 
neurological deterioration (END), predominantly defined in literature as an increase in NIH 
Stroke Scale (NIHSS) score by 4 or more points, is strongly related to poor long-term 
functional outcome.14, 15 Radiologically proven arterial occlusion in patients with minor stroke 
is a well-established predictor of early deterioration and disability.16, 17 However, it is still 
unclear which patients with minor stroke, and which occluded arterial segments, have the 
highest risk of deterioration despite IV tPA and could potentially be spared disability through 
early endovascular therapy. The randomised controlled trials of mechanical thrombectomy 
published in 2015 excluded, or enrolled very few, patients with NIHSS score < 6, thus unable 
to address efficacy and safety of treatment in this group.18 The 2015 American Stroke 
Association guideline update expressed that endovascular therapy "may be reasonable" in 
minor stroke caused by internal carotid artery (ICA) or proximal part of the middle cerebral 
artery (MCA-M1) occlusion, making no mention of patients with minor stroke caused by 
other arterial occlusions.19 Considering a potential reluctance among clinicians to recommend 
patients with minor stroke symptoms for an invasive procedure, the overarching aim of our 
present study is to facilitate the identification of patients in whom the initial "minor stroke" 
presentation masks a more ominous condition. 
The primary objective of this study was to determine the frequency of early, non-hemorrhagic 
neurological deterioration in patients who receive IVT for minor stroke caused by occlusion 
of specific cerebral arteries, including both large, proximal vessels and more distal ones. The 
secondary objectives were to establish risk factors for early neurological deterioration, and 
report three month functional outcomes and mortality in patients with and without END. 
  
Methods 
We analysed patient data recorded in the SITS International Stroke Thrombolysis Register 
(SITS-ISTR) between December 1, 2012 and April 25, 2016. Patients treated with IV 
alteplase (Actilyse, Boehringer-Ingelheim, Germany), with confirmed baseline data entered 
using the standard IVT case report form (N=34566) were considered. The study period was 
based on the time of implementation in the SITS database of optional variables for registering 
detailed information on sites of arterial occlusion using CT or MR angiography (CTA/MRA) 
performed at baseline. We further required availability of complete NIHSS evaluation at 
baseline, and only included patients with baseline total NIHSS scores between 0 and 5 
(n=6860). Vessel occlusion was defined as complete occlusion or <50% filling of the vascular 
territory. Furthermore, patients who had any endovascular procedure (thrombectomy, extra- 
or intracranial stenting or angioplasty, intraarterial thrombolysis) performed during the acute 
hospital stay were excluded from the analysis in order to isolate the study population to 
patients who received only IVT as the causal therapy for arterial recanalisation. This 
exclusion was also necessitated by the fact that the SITS-ISTR IVT data form does not 
contain exact time-points of performed endovascular treatments, making it impossible to 
discern if the procedures were done before or after the times of NIHSS evaluation (collected 
at baseline, at 2 hours and at 24 hours after start of IVT). 
The SITS-ISTR is an ongoing, prospective, academic-driven, multinational register for 
centers using thrombolysis for the treatment of acute ischemic stroke. The methodology of the 
SITS-ISTR, including procedures for data collection and management, patient identification 
and verification of source data, has been described previously.20, 21 Consecutive case reporting 
is a basic commitment for participating in the SITS-ISTR. We collected baseline and 
demographic characteristics, stroke severity per the standard 11-item, 42-point NIHSS, time 
logistics, medication history, and imaging data on admission and follow-up. Assessment of 
imaging studies, neurological and functional status were done according to clinical 
routine at centers participating in the SITS-ISTR, with no additional central 
adjudication. 
Ethics approval and data monitoring 
Ethics approval was obtained from the Stockholm Regional Ethics Committee for this project 
as part of the SITS-MOST II study framework. Ethics approval and patient consent for 
participation in the SITS-ISTR were obtained in countries that required this; other countries 
approved the register for anonymized audit. The SITS International Coordination Office 
monitored the SITS-ISTR data online and checked individual patient data monthly to identify 
errors or inconsistencies. 
Outcome measurements 
Non hemorrhagic early neurological deterioration (nhEND) was defined as increase in NIHSS 
score ≥4 within 24 hours after IVT, with no parenchymal hematoma (PH) of any size or 
location on routine follow-up imaging at 22-36 hours, or earlier, if clinically indicated. 
Functional outcomes and mortality were assessed at three month follow-up using the modified 
Rankin Scale (mRS), with poor outcome defined as mRS 3-6.  
Statistical analysis 
We performed descriptive univariate statistics for baseline clinical and imaging data, as well 
as outcomes, comparing patients with and without nhEND. For continuous and ordinal 
variables, median and interquartile range values were calculated. For categorical variables, we 
calculated percentage proportions by dividing the number of events by the total number of 
patients, excluding missing or unknown cases, as done in previous SITS publications.21-23 For 
calculation of significance of difference between medians and proportions we used the Mann-
Whitney U-test and the Pearson χ2 method, respectively. Furthermore, we calculated the 
sensitivity, specificity, positive and negative predictive values (PPV and NPV) of CTA/MRA 
at baseline to detect patients who would go on to develop nhEND. To investigate the 
association between nhEND and clinical and radiological parameters, multivariate logistic 
regression analysis was performed adjusting for baseline variables showing a positive 
association with nhEND at the p≤0.10 level in univariate analysis. In this analysis, variables 
significant at p<0.05 were regarded as independent risk factors for nhEND. Analyses were 
performed using STATISTICA 13.0 (Dell Inc, Tulsa, OK, USA). 
Results 
A total of 2553 patients from 241 hospitals in 34 countries comprised the study cohort. 
(Figure 1). CTA was the baseline vessel imaging modality in 2437 (95.5%) cases and MRA in 
116 (4.5%). The distribution of arterial occlusion sites among study patients is shown in Table 
1. 
Site of occlusion N=2553 % of N 
% of all 
occlusions 
ICA-T or ICA+MCA 20 0,8% 3,1% 
ICA 101 4,0% 15,9% 
ACA 13 0,5% 2,0% 
MCA-M1 92 3,6% 14,5% 
MCA-M2 147 5,8% 23,1% 
MCA-M3 39 1,5% 6,1% 
PCA 51 2,0% 8,0% 
Basilar 32 1,3% 5,0% 
Vertebral 62 2,4% 9,8% 
Site unspecified 78 3.1% 12,3% 
Any occlusion 635 24.9%  
No occlusion 1918 75.1%  
 
Table 1. Arterial occlusion sites in patients with minor stroke treated with IVT. ICA-T: 
terminal internal carotid artery; ICA+MCA: tandem ICA and middle cerebral artery 
occlusion; ACA: anterior cerebral artery; M1, M2, M3: first, second and third segments of 
the MCA; PCA: posterior cerebral artery. 
Data from follow-up imaging at 22-36 hours or earlier (if performed due to clinical 
indication) were available in 606/635 (95.4%) patients with arterial occlusion at baseline, and 
1810/1918 (94.4%) patients with no occlusion. Clinical follow-up data at 24 hours were 
available in 2481/2553 patients (97.2%). Parenchymal hematoma (PH, any size and location) 
was seen in 18/606 (3.0%) patients with occlusions, and 55/1810 (3.0%) patients without 
occlusions, p=0.93.  
 
In patients without PH and with available 24 hour neurological follow-up (n=2336), early 
neurological deterioration occurred in 53/587 (9.0%) of those with any arterial occlusion 
compared to 55/1749 (3.1%) of those with no occlusion, p<0.001. Based on these numbers, 
we could calculate a sensitivity of 49.1%, specificity of 76.0%, PPV of 9.0%, and NPV of 
96.9% for baseline vessel imaging to predict nhEND in patients treated with IVT for minor 
acute ischemic stroke. 
 
The highest frequency of nhEND at 30.0% was seen in patients who had terminal carotid 
(ICA-T) or tandem ICA+MCA occlusions, and the lowest in patients with M3-MCA and 
posterior cerebral artery (PCA) occlusions at 0% and 2.2% respectively (Table 2). 
 
 
  
 Site of occlusion nhEND 
n/N 
nhEND  
% (95% CI) 
P aOR (95% CI) 
for nhEND 
P 
ICA-T or ICA+MCA 6/20 30.0% (14.6-51.9%) < 0.001 10.3 (4.3-24.9) < 0.001 
ICA 16/96 16.7% (10.5-25.4%) < 0.001 4.3 (2.5-7.7) < 0.001 
ACA 2/12 16.7% (4.7-44.8%) 0.008 5.9 (1.6-22.1) 0.008 
MCA-M1 8/86 9.3% (4.8-17.3%) 0.002 2.1 (0.97-4.4) 0.061 
MCA-M2 8/137 5.8% (3.0-11.1%) 0.091 1.6 (0.8-3.1) 0.14 
MCA-M3 0/35 0.0% (0.0-9.9%) 0.287 0.6 (0.1-4.2) 0.57 
PCA 1/46 2.2% (0.4-11.3%) 0.709 0.4 (0.1-3.2) 0.41 
Basilar 3/29 10.3% (3.6-26.4%) 0.030 2.0 (0.6-6.6) 0.26 
Vertebral 4/56 7.1% (2.8-17.0%) 0.098 2.3 (0.96-5.5) 0.063 
Site unspecified 5/70 7.1% (3.1-15.7%) 0.094 2.7 (1.3-5.7) 0.007 
Any occlusion 53/587 9.0% (7.0-11.6%) < 0.001 2.5 (1.7-3.4) <0.001 
No occlusion 55/1749 3.1% (2.4-4.1%) Ref. Ref. Ref. 
 
Table 2. Proportion of patients with non-hemorrhage related END (nhEND) and adjusted 
odds ratios (aOR) for nhEND by site of arterial occlusion at baseline. nhEND: increase in 
NIHSS score  ≥ 4 at 24 hours with no parenchymal hematoma on follow-up imaging within 
22-36 hours. Ref: reference. Patients with no visible arterial occlusion on baseline CTA/MRA 
were used as reference for comparison.  
 
In the population with minor stroke and visible arterial occlusion, patients with and without 
nhEND had comparable medical history and baseline clinical parameters, with the exception 
of congestive heart failure, which was seen in 11% vs 5% (p=0.049) (Table 3). Large artery 
atherosclerosis was somewhat more often the cause of stroke in patients with nhEND, at 56% 
vs 42.5%, trending toward significance (p=0.066). 
  
  
nhEND, n=53 
 
No nhEND, n=534 
 
 
No./Total Median (IQR) or % No./Total Median (IQR) or % p Value 
Patient history 
     
Age 53 67 (59-75) 533 67 (57-76) 0.97 
Sex (f) 18/53 34.0% 189/534 35.4% 0.84 
AF 4/53 7.5% 88/532 16.5% 0.11 
Heart failure 6/53 11.3% 26/532 4.9% 0.049 
HT 39/53 73.6% 341/533 64.0% 0.16 
DM 14/53 26.4% 91/532 17.1% 0.09 
Hyperlipidemia 16/53 30.2% 185/528 35.0% 0.48 
Previous stroke 4/53 7.5% 46/531 8.7% 0.78 
AP or OAC treatment 18/53 34.0% 208/534 39.0% 0.48 
Current smoker 13/53 24.5% 85/509 16.7% 0.15 
Previous smoker 2/49 4.1% 69/495 13.9% 0.051 
Clinical parameters 
     
NIHSS 53 4 (3-5) 534 4 (3-5) 0.12 
OTT 52 165 (121-218) 514 160 (125-210) 0.57 
SBP  51 160 (141-180) 529 156 (140-170) 0.11 
DBP 51 85 (75-95) 529 81 (75-92) 0.53 
SBP 24h 48 140 (130-157) 500 137 (124-150) 0.015 
DBP 24h 48 80 (70-84) 500 76 (70-82) 0.47 
Glucose  47 7.0 (6.0-8.5) 518 6.5 (5.7-7.8) 0.071 
Etiological classification     
Large artery atherosc. 28/50 56.0% 214/504 42.5% 0.066 
Cardioembolic 9/50 18.0% 131/504 26.0% 0.21 
Other or undetermined 13/50 26.0% 159/504 31.5% 0.42 
 
Table 3. Clinical characteristics of patients with baseline arterial occlusion, with and without 
non-hemorrhage related END (nhEND). nhEND: increase in NIHSS score  ≥ 4 at 24 hours 
with no parenchymal hematoma on follow-up imaging within 22-36 hours. AF: atrial 
fibrillation; HT: hypertension; DM: diabetes mellitus; AP: antiplatelet drugs; OAC: oral 
anticoagulants; NIHSS: NIH Stroke Scale; OTT: onset-to-treatment time; SBP: systolic blood 
pressure; DBP: diastolic blood pressure. All clinical parameters measured at baseline unless 
specified. 
  
In patients with nhEND, ICA occlusion was present in 22/53 (41.5%) versus 94/534 (17.6%) 
in those without nhEND, p<0.001. This should be seen in the context that ICA occlusion was 
present in 121/635 (19%) of all patients with visible occlusions (Table 1). A comparison of 
distribution of arterial sites between the groups with and without nhEND did not show any 
other significant difference. M2-MCA and M3-MCA occlusions were under-represented, 
however, in the nhEND group at 15% and 0% compared to 24% and 7% in the group without 
nhEND (Online Table 1). 
 
In multivariate analysis (Table 2), any visible arterial occlusion at baseline was the only 
independent predictor for nhEND, with an adjusted odds ratio (aOR) of 2.5, p<0.001. When 
"any occlusion" was substituted in the multivariate model for the detailed "specified site of 
occlusion" variable, the independent predictors of nhEND remained: ICA-T or ICA+MCA 
with aOR 10.3, ICA with aOR 4.3, and ACA with aOR 5.9. The remaining variables included 
in the multivariate model, heart failure, diabetes, glucose (included per the univariate p≤0.10 
cut point specified in Methods) and other occlusion sites, did not show significant 
relationships with nhEND. However, MCA-M1 occlusion (aOR 2.1, p=0.06), Vertebral artery 
occlusion (aOR 2.3, p=0.06), Heart failure (aOR 1.8 (0.95-3.4), p=0.07) and Diabetes (aOR 
1.4 (0.95-2.2), p=0.08) trended toward significance, while baseline blood glucose did not 
show a significant association, p=0.60 (Online Supplement Table 3). 
 
Patients who suffered nhEND after a minor stroke treated with IVT had poor three month 
outcomes. Only 23% attained mRS 0-2 in the presence of a baseline occlusion, and 35% 
among those without an occlusion (Figure 2). Meanwhile, patients who avoided nhEND fared 
much better, with frequencies of mRS 0-2 at 88% and 92% (with and without occlusion, 
respectively). In the group with occlusion at baseline, among the 80 patients with poor three 
month outcomes (mRS 3-6), 35% had suffered nhEND, while 9% had deterioration associated 
with PH on follow-up imaging.  
The worst three month outcomes were seen in the group with ICA-T or ICA-MCA occlusions 
(mRS 3-6 in 42%), followed by those with occlusion of the ACA (40%), MCA-M1 (20%), 
basilar artery (19%), vertebral artery (18%), and ICA (17%). Patients with occlusions of M2-
MCA, M3-MCA, PCA and those without visible occlusion all had proportions of poor 
outcomes between 10% and 12% (Online Figure 1).  
Discussion 
The clinical scenario of an IVT-treated patient with minor stroke symptoms due to a imaging-
proven arterial occlusion is not uncommon. In the SITS-ISTR, during the current study 
period, 21% of patients treated with IVT for acute ischemic stroke had NIHSS scores 0 to 5, 
which is in agreement with data from the Get With the Guidelines registry, reporting 22%.24 
In our material, 25% of patients had a visible arterial occlusion on baseline imaging. In 
previously published cohorts of minor stroke patients treated and untreated with IVT, 14-54% 
are reported to have a baseline arterial occlusion. The wide variation is explained by 
differences in definitions of minor stroke and arterial occlusion, treatment status and other 
cohort specifics; however, many publications report occlusion frequencies above 30%.5, 25-28 
In patients with minor stroke due to large artery occlusion, there is no clear evidence on the 
best course of action beyond IVT therapy, and it is currently unknown whether, and in whom, 
endovascular recanalisation would be beneficial. 
We present a large observational study of patients in this situation, giving estimates of 
prognosis in relation to the location of arterial occlusion. Patients with minor stroke are at 
high risk of severe neurological deterioration and poor long-term outcome particularly if the 
stroke is caused by occlusion of the ICA. It is especially true in the presence of ICA-T and 
tandem ICA+MCA occlusion, where 30% of patients will deteriorate severely (and not due to 
SICH) by the second day of hospital stay – a 10-fold increase in the risk of nhEND compared 
to patients without visible occlusion at baseline. This makes the "minor" in the initial 
presentation a misnomer. Preventing deterioration in patients with proven arterial occlusion is 
of paramount importance, as 77% of those who suffer nhEND will be dead or dependent 
(mRS 3-6) at three months, despite presenting with NIHSS scores 0-5. Put in perspective, 
these outcomes are worse than in patients treated with IVT for severe stroke (NIHSS score 
15-25), where 71% are dead or dependent at three months.23  
Regarding the particularly high risk for nhEND in patients with occlusion of the ICA (aOR 
4.3) and ICA-T or ICA+MCA (aOR 10.3), our findings are in line with results from 
previously published studies. In the SAMURAI rt-PA registry, ICA occlusion had an adjusted 
OR for END of 5.4.6 However, the study investigated END in unselected thrombolysed 
patients, and did not report on minor stroke specifically. One study of patients with minor 
stroke (NIHSS 0-3) untreated with IVT, also reported a strong association of ICA occlusion 
with severe END, with aOR 6.5.5 In our study, IVT-treated minor stroke patients with 
occlusions of the MCA-M1, basilar artery and ACA faced a lower, but still significantly 
increased risk of nhEND, with a 3- to 5-fold increase compared to patients without visible 
occlusion at baseline. It is important to note that MCA-M1 occlusions, in spite of not 
quite reaching statistical significance in multivariate analysis (aOR 2.1, 95% CI 0.97-4.4, 
p=0.061), had a 9.3% crude rate of deterioration. It is possible that this moderately 
increased risk can be explained by the fact that these patients present with NIHSS 0-5 in 
spite of having MCA-M1 occlusion, which could indicate robust collateral circulation or 
incomplete occlusion with some degree of patency left in the M1 and therefore higher 
likelihood of effective thrombolysis.29  
Our findings on ACA occlusions are difficult to interpret, as patients with ACA 
occlusions were very few, n=13 in total, 2% of all visible occlusions and 0.5% of the 
entire NIHSS 0-5 cohort. Of these, 1 had a parenchymal hemorrhage and was excluded 
(per the Methods section) and of the remaining 12, 2 patients had nhEND (~16.7%). It is 
not impossible that the two deteriorating patients could have had very proximal A1 
occlusions just after the ICA terminus. In such cases, deterioration could have occurred 
due to retrograde thrombus propagation (build-up) into the terminal ICA and/or M1. 
However, our data lack the level of detail necessary to elucidate this in further detail. 
In minor stroke without arterial occlusion on baseline imaging, nhEND was uncommon, 
occurring in only 3% of patients, of whom nearly two thirds had poor three month outcomes. 
We have no data on the causes of neurological deterioration in these cases, but in light of the 
relative rarity of this complication when there is no occlusion, the mechanisms are likely to be 
heterogeneous, including, among others, recurrent (e.g. cardioembolic) or progressive (e.g. 
microangiopathic) cerebral ischemia with a variety of causes.  
Due to a lack of data on cerebral hemodynamics and infarct volumes, we are unable to present 
direct evidence on the mechanisms of nhEND in patients with baseline arterial occlusion. 
Meanwhile, using clinical data and etiological stroke classification, we can infer that: (1) 
nhEND could only infrequently have occurred due to early recurrence of cardioembolism, as 
only 7,5% of deteriorated patients had atrial fibrillation at baseline and 18% of the strokes 
were cardioembolic, compared to 16.5% and 26% respectively in the non-deteriorated group; 
(2) deterioration due to cerebral edema within the primary infarct is unlikely among patients 
with a baseline stroke severity of NIHSS 0-5; (3) systemic hypotension is unlikely to have 
been a major factor in nhEND, in whom the frequency of congestive heart failure was 11.3% 
and median 24 hour blood pressure was 140/80. We surmise that two likely mechanisms for 
nhEND in our patients remain: collateral circulation failure10-12 and/or progressive 
thrombosis15, 30, 31, either leading to infarction of initially functional, non-penumbral tissue.32, 
33 The former would be supported by the low initial symptom severity, which in the presence 
of a proximal large artery occlusion would indicate good collateral flow to the downstream 
territory.34 The latter gains support from the somewhat higher proportion of large artery 
atherosclerosis as cause of stroke among nhEND patients, also reported in previous 
publications.5, 35  
There is currently no established therapy to maintain collateral flow. For progressive 
thrombosis, very early (within hours following IVT) antithrombotic therapy could 
theoretically prevent nhEND. There is no evidence for benefit of this strategy, however; rather 
the contrary, as aspirin loading within 24 hours from IVT has been shown to increase the risk 
of SICH.36 Thus, in patients at the highest risk of nhEND, despite low baseline NIHSS scores, 
it may be reasonable to consider acute treatment with endovascular thrombectomy and/or 
cervical ICA recanalisation. This conclusion is in line with the current consensus statement on 
treatment issued by the European Stroke Organisation – Karolinska Stroke Update and 
endorsed by several European professional societies. It recommends thrombectomy in 
addition to IVT in patients with large artery occlusion up to 6 hours from symptom onset, 
purposefully omitting the issue of initial symptom severity to allow for an individualised 
approach to treatment.37 An alternative course of action would be to ensure that patients with 
occlusions in the most deterioration-prone vessel segments are held under intensive 
neurological monitoring for at least 24 hours from onset at a comprehensive stroke center to 
enable rapid endovascular rescue treatment if deterioration should occur. Meanwhile, a 
number of publications have recently appeared on the topic of primary versus 
deterioration-driven thrombectomy versus medical therapy alone in minor stroke 
patients. Although based on small cohorts, these early results indicate that primary 
intervention may potentially be superior to both deterioration-driven thrombectomy 
and medical therapy.38-40 This warrants further confirmation, ideally in the setting of at 
least one multi-centre randomised trial.  
In our study, acute vessel imaging in IVT-treated minor stroke patients had a 9% PPV and 
97% NPV for nhEND. Despite the initial "minor" presentation, patients who suffer non-
hemorrhage related deterioration have in effect a disease which leads to outcomes as poor, or 
worse, as in IVT-treated severe stroke: a 77% probability of death or dependence by three 
months. In patients with the highest risk of nhEND, i e those with proximal cerebral artery 
occlusions, such outcomes may be preventable by acute endovascular treatment. To identify 
these potentially treatable cases, acute vessel imaging should preferably be performed 
routinely in all patients with acute ischemic stroke regardless of symptom severity. As an 
additional benefit, acute imaging allows earlier decision-making regarding carotid 
endarterectomy in patients who harbour significant carotid stenosis, a more rapid and better 
informed individualisation of etiological workup and secondary preventive treatment. The 
corollary also applies: the negative predictive value of 97% indicates that minor stroke in 
absence of vessel occlusion in the majority of cases has a benign prognosis, which may guide 
decisions on early neurological monitoring and discharge planning. 
The results of this study are subject to limitations inherent to observational design. Similar to 
the situation in other large-scale registries, the data in the SITS-ISTR, while having the 
benefit of being representative of a wide range of practice settings and countries, is collected 
with no independent adjudication. Of 6860 patients with minor stroke and IVT treatment 
collected in our database between 2012 and 2016, 2620 (38%) had relevant baseline vessel 
imaging performed. This is reflective of practice in many centres and countries, where CTA 
or MRA are not routinely used in minor stroke, and in others, are used selectively. These 
numbers do raise the question of potential patient selection bias. However, we report 25% of 
patients with visible occlusions, and many recent publications have reported proportions 
above 30%.5, 25-28 This would limit the likelihood that patients in our material were selected 
for vessel imaging based on any unregistered factors increasing their likelihood of harbouring 
an occlusion. In order to analyse nhEND in a cohort treated with only IVT, from our initial 
population of 2620 patients, we excluded 67 (2.6%) patients who had undergone endovascular 
therapy (Online Table 2). In particular, since 10 of 39 patients with basilar artery 
occlusion were excluded for this reason, our results in this group need to be interpreted 
with caution. The exclusion may have been a source of selection bias potentially lowering the 
proportion of nhEND in our results, since endovascular therapy in some of the excluded 
patients could have been performed because of early neurological deterioration, or if done in 
the hyperacute phase, might have prevented deterioration.  An important limiting factor for 
the interpretation of our results on extracranial ICA occlusion is our inability to 
discriminate between complete occlusion and significant stenosis of the vessel based on 
the SITS database structure. This limits our conclusions on ICA occlusion in minor 
stroke to a recommendation on close neurological monitoring and need for further 
studies on the prevention of clinical deterioration due to ICA pathology in the ultra-
acute phase of stroke. A further limitation requiring mention is the relatively high proportion 
of patients without available 3 month outcome data, 31%. Importantly, this does not influence 
the interpretation of results pertaining to our primary aim: to study early deterioration in 
relation to occlusion sites in minor stroke. Meanwhile, it warrants caution in the interpretation 
of our secondary analyses of long-term functional outcome. While acknowledging this, one 
must still note that patients with early neurological deterioration have been extensively shown 
in prior publications to have a very poor prognosis,14, 15 which we were able to confirm even 
in the presence of the mentioned limitations. 
Conclusion 
Patients with apparently minor stroke associated with occlusion of the ICA, with or without 
tandem MCA involvement, are at high risk of disabling deterioration, despite IVT treatment. 
Acute vessel imaging contributes usefully even in minor stroke patients to identify and 
consider acute endovascular treatment or intensive neurological monitoring at a 
neuroendovascular centre, for those who may be at high risk of potentially preventable 
deterioration. A randomized controlled trial of endovascular treatment versus best 
medical management including thrombolysis in patients with minor stroke is urgently 
needed.   
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Figure 1. Patient selection flow diagram. 
 
  
Patients treated with IVT for acute ischemic 
stroke between 2012-12-01 and 2016-04-25, with 
confirmed baseline data (n=34566) 
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Figure 2. Outcomes per the modified Rankin Scale (mRS) at 3 months by arterial occlusion 
and nhEND status. nhEND: non-hemorrhagic neurological deterioration. 
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